Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non …

W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2011 - ascopubs.org
Purpose The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …
被引用次数：334 相关文章

[引用][C] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non …

W BRUGGER, N TRILLER, K TRUNZER… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled
Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer CNRS …

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non …

W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2011 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> The phase III, randomized, placebo-
controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study found …

[引用][C] Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non …

W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2011 - elibrary.ru

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell …

W Brugger, N Triller… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small …

W Brugger, N Triller, M Blasinska-Morawiec… - Journal of clinical …, 2011 - lsmu.lt
Purpose. The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell …

W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2011 - europepmc.org
Purpose The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …